TNFi in Psoriatic diseases

Speciality: Dermatology


Speaker:

Dr. Vijaya Prasanna - Speaker | Rheumatologist

Dr. Swapna Priya - Speaker | Dermatologist

Description:

A warm welcome to all the medical professionals in this interesting session on tnfi in Psoriatic diseases
TNF inhibitors (TNFi) have transformed the treatment of psoriatic diseases, including both psoriasis and psoriatic arthritis. These biologic therapies target tumor necrosis factor-alpha (TNF-α), a key cytokine involved in the inflammatory process that drives these conditions. Clinical trials and real-world evidence demonstrate that TNFi effectively reduce skin lesions, alleviate joint pain, and prevent further joint damage in psoriatic arthritis patients.
TNFi are often prescribed when traditional systemic therapies fail to control symptoms. Medications such as infliximab, etanercept, and adalimumab have shown significant success in improving quality of life for patients with moderate to severe disease. While highly effective, TNFi treatments require ongoing monitoring due to potential side effects, such as an increased risk of infections. Nevertheless, TNFi remain a cornerstone in the management of psoriatic diseases, offering relief to many who struggle with these chronic conditions.
Therefore, get an overall knowledge of tnfi in Psoriatic diseases. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot